
|Articles|September 16, 2014
Combination Treatment for HIV/HCV Coinfection Shown Effective in Phase 3 Trial
Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.
Advertisement
Results of a phase 3 study published September 6, 2014 in the journal Clinical Infectious Disease demonstrates the efficacy of Janssen's simeprevir (Olysio) in combination with peginterferon and ribavirin in patients with genotype-1 hepatitis C and HIV-1 coinfection.
To read the rest of the article on
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Peptide Reclassification Everyone's Talking About: A Pharmacist's Take on What RFK Jr's Announcement Actually Means
2
ADA 2026: Earlier GLP-1 and SGLT-2 Use Recommended From Diabetes Diagnosis, Expert Says
3
Brain Inflammation May Not Drive Persistent Long COVID Symptoms, New Imaging Study Finds
4
ADA 2026: Semaglutide Add-On Reduces Glycemic Burden, Cardiometabolic Risk in Older Adults With T2D
5





































































































































